Drug Profile
S 37435
Alternative Names: Growth hormone secretagogues research programme - Kaken; Research programme: growth hormone secretagogues - KakenLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Kaken Pharmaceutical
- Class
- Mechanism of Action Growth hormone releasing factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Dwarfism
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Dwarfism in Japan
- 07 May 2002 S 37435 is the lead compound of the programme
- 30 May 2001 Preclinical development for Dwarfism in Japan (Unknown route)